Unleashing the Future of Therapeutics: Antibody Discovery

When we think of medicine, most of us picture a pill. Maybe acetaminophen for a headache or an antibiotic for an infection—tiny, chemically synthesized molecules designed to tweak our biochemistry just enough to set things right. But there’s another class of drugs that’s not only changing the way we treat disease but also reshaping the future of medicine itself: biologics. And leading that revolution are antibodies.

You’re making them right now. Billions of them, in fact. These Y-shaped proteins are custom-built by your immune system to identify and neutralize invaders. What makes antibodies so powerful is their precision—each one crafted to recognize a specific target. That same precision is what makes them such promising therapeutics.

Why Antibodies Matter

Antibodies work like molecular bounty hunters." They circulate through the body, recognize specific foreign invaders (pathogens or toxins) based on unique markers (antigens), and then tag them for destruction or directly neutralize them, much like a bounty hunter tracks down and apprehends a target. They have a constant region—the part that stays the same across different antibodies—and a variable region that’s tailored to lock onto a unique target. That target might be a viral protein, a cancer cell marker, or a rogue molecule stirring up an autoimmune reaction.

If scientists can discover or engineer an antibody that binds only to a disease-causing molecule, they can turn it into a highly selective treatment. And they’ve already done it—many times over.

Antibodies are the backbone of immunotherapy, helping unleash the immune system to fight off tumors. They’ve been game-changers in treating inflammatory conditions, and infectious diseases. More than 100 monoclonal antibodies have been approved by the FDA, and hundreds more are in development. Simply put, they’re the fastest-growing class of drugs today.

Antibodies are Y-shaped proteins composed of two identical heavy chains and two identical light chains. Each chain includes an N-terminal variable domain, responsible for antigen recognition, and one or more C-terminal constant domains that define the antibody's class and function. At the tips of the "Y" lie the variable regions (Fab regions), where sequence diversity enables recognition of a vast range of antigens. Within these regions are complementarity-determining regions (CDRs)—three per chain—that directly contact the antigen. The base of the Y forms the constant region (Fc region), which interacts with components of the immune system to mediate effector functions such as phagocytosis or cell lysis. The chains are held together by disulfide bonds—between the two heavy chains and between each heavy and light chain—stabilizing the antibody’s structure.

What Do We Mean by "Antibody Discovery"?

At its heart, antibody discovery is the search for that one-in-a-million molecule. It starts with identifying a biological target—say, a receptor on a cancer cell or a protein on a virus—and ends (hopefully) with a safe, effective therapeutic that binds tightly to that target and does something useful: blocks it, activates it, flags it for destruction, or delivers a toxic punch.

But finding that perfect antibody isn’t as simple as it sounds. You’re essentially looking for a single immune cell—just one—that produces the antibody with the right combination of specificity and affinity. The search involves screening through massive libraries of candidates, then optimizing the best ones through a mix of engineering, evolution, and clever, creative, and original thinking to overcome challenges and achieve successful outcomes.

How We Got Here: A Bit of History

Back in the 1970s, César Milstein and Georges Köhler—working at the Laboratory of Molecular Biology (LMB), where I was lucky to do my postdoc—figured out how to produce monoclonal antibodies: identical copies of a single antibody made in the lab. By fusing antibody-producing B cells with cancer cells, they created hybridomas that could churn out antibodies indefinitely. Their groundbreaking work earned them a Nobel Prize and laid the foundation for today’s antibody-based therapies.

Since then, the field has taken off. Advances like phage display, yeast display, single B cell screening, and recombinant engineering have unlocked entirely new ways to explore the antibody universe. We’re no longer limited by nature’s offerings—we can now build synthetic libraries, tweak binding properties, humanize sequences, fragment antibodies, or fuse them with other molecules to create entirely new formats.

The Discovery Journey

So how do we go from a bright idea to a working therapy? The process usually kicks off with identifying a suitable target. Researchers look for molecules that play a role in disease—and make sure those molecules are specific enough that targeting them won’t cause collateral damage.

Once the target is validated, it’s time to generate antibodies. That might mean immunizing animals, fishing antibodies from convalescent patients, or building synthetic libraries displayed on the surface of viruses, yeast, or even mRNA.

From there, it’s all about screening. Scientists test candidates for how tightly they bind (affinity), how selectively they bind (specificity), and what happens when they bind (do they block a signal, or activate a response?). The best ones are then optimized—engineered for better stability, lower immunogenicity, or improved delivery to tissues.

Eventually, a handful of finalists make it to preclinical and clinical trials. They’re tested in cells, animals, and ultimately people to see how well and safely they work.

A New Toolbox of Antibody Formats

While full-length IgG antibodies are still the standard, they’re no longer the only game in town. Scientists have created all sorts of alternative formats: antibody fragments, bispecific antibodies, nanobodies, and antibody-drug conjugates (ADCs). Each format offers something different—better tissue penetration, the ability to cross the blood-brain barrier, or the power to engage multiple targets at once.

This flexibility means that antibodies can now be tailored to the disease and the patient. It's no longer one-size-fits-all.

Putting Antibodies to Work

Monoclonal antibodies (mAbs) are like guided missiles for the immune system. Once they bind to their target, they can do a number of things—neutralize harmful molecules, block cellular signals, flag diseased cells for destruction, or deliver lethal cargo. Let’s look at how they operate in the real world:

Neutralization: In autoimmune diseases, some mAbs mop up excess cytokines. Adalimumab (Humira) blocks TNF-α, a major inflammatory culprit.

Blocking receptors: Cancer cells often overexpress growth receptors. Trastuzumab (Herceptin) blocks HER2 to stop aggressive breast tumors from growing.

Immune recruitment: Some mAbs call in immune cells to kill whatever they’ve tagged. Rituximab targets CD20 on B cells, marking them for destruction in lymphomas.

Payload delivery: ADCs like Brentuximab vedotin deliver toxic agents directly to cancer cells, sparing healthy tissues.

Checkpoint inhibition: mAbs like Nivolumab unleash the immune system by blocking PD-1, an “off switch” used by cancer cells to avoid attack.

Infection blockade: Palivizumab binds RSV to protect vulnerable infants from infection.

Protein aggregate clearance: Experimental mAbs like Aducanumab aim to clear amyloid plaques in Alzheimer’s, though results remain controversial.

Discovery at Scale: Display Technologies

One of the most transformative tools in antibody discovery has been cell surface display. Whether it’s phage display, yeast display, or mRNA display, the idea is simple: create a massive library of antibody fragments and stick them on the surface of something—like a virus or a yeast cell. Then, expose them to the target. The binders stick. Everything else gets washed away.

Because each displayed antibody is linked to its genetic code, scientists can quickly sequence the “winners” and turn them into full antibodies. These platforms not only speed up discovery—they also allow for fine-tuning, testing, and evolution of antibody candidates in real time.

Looking Ahead

We’re just getting started.

Antibody engineering is becoming smarter, faster, and more personalized. Bispecific and multispecific antibodies are allowing us to engage multiple disease pathways at once. ADCs are combining antibodies with potent drugs to hit cancer where it hurts. AI and in silico prediction tools are helping design antibodies from scratch—sequences that nature never dreamed of.

There’s even a vision of tailoring antibody therapies to individuals based on their immune repertoires—an era of personalized antibody medicine.

And when the next pandemic hits? We’ve seen how quickly antibody discovery platforms can be mobilized. During COVID-19, monoclonal antibodies were in clinical use within months—a feat made possible by decades of innovation.

The Future is Antibody-Shaped

Antibody discovery is no walk in the park. It demands rigorous target validation, massive screening efforts, and painstaking optimization. Poorly chosen targets or low-quality antibodies can derail a whole program. But we’ve developed the tools to overcome these hurdles—technologies like phage display, single B-cell sequencing, and machine-learning-guided engineering have made the impossible more feasible than ever.

From cancer and autoimmune diseases to Alzheimer’s and infectious threats, antibodies are transforming what medicine can do. And as we continue to refine and reinvent the ways we discover and deploy them, the future of therapeutics may not come in a pill bottle—but in a protein, inspired by your own immune system.

Would you like to stay updated on the latest breakthroughs in biomedical science? 

Subscribe to my blog and join me in exploring the next frontier of medicine!